OUTLOOK THERAPEUTICS INC (OTLK NASDAQ) stock market data APIs
$0.756
0.08(10.6%)
as of August 14, 2026
Try our APIs with
free plan!
OUTLOOK THERAPEUTICS INC Financial Data Overview
Price chart is built with
Anychart
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Prev. Close
0.756
Open
0.8378
High
0.8403
Low
0.7148
52 wk Range
0.1611-3.39
Market Cap
141 M
Shares Outstanding
187 M
Revenue
333 K
EPS
-0.09
Beta
0.804
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with OUTLOOK THERAPEUTICS INC (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get OUTLOOK THERAPEUTICS INC data using free add-ons & libraries
Get OUTLOOK THERAPEUTICS INC Fundamental Data
OUTLOOK THERAPEUTICS INC Fundamental data includes:
- Net Revenue: 333 K
- EBITDA: -60 454 584
- Earnings Per Share: -1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get OUTLOOK THERAPEUTICS INC Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-08-14
- EPS/Forecast: -0.09
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
OUTLOOK THERAPEUTICS INC News
New
Oncobiologics Q3 Earnings Call Highlights
Key Points Interested in Oncobiologics, Inc.? Here are five stocks we like better. FDA approval clears the way for LYTENAVA's U.S. launch later this year as the only FDA-approved ophthalmic bevacizum...
Zealand Pharma A/S (ZLDPF) Surpasses Q2 Earnings and Revenue Estimates
Zealand Pharma A/S (ZLDPF) came out with quarterly earnings of $8.61 per share, beating the Zacks Consensus Estimate of a loss of $0.42 per share. This compares to earnings of $16.06 per share a year ...
Outlook Therapeutics slides after pricing $55M securities offering
Outlook Therapeutics (OTLK [https://seekingalpha.com/symbol/OTLK]) shares fell nearly 15% in premarket trading Thursday after the company priced a public offering of 55.6M shares and warrants for gros...
Outlook Therapeutics Prices $55 Mln Offering To Support LYTENAVA Launch; Stock Down
(RTTNews) - Outlook Therapeutics, Inc. (OTLK), a biopharmaceutical company, priced a public offering of 55.56 million shares and accompanying warrants to purchase up to 55.56 million shares at a combi...
Get OUTLOOK THERAPEUTICS INC fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
